Optimal post-treatment surveillance strategy for human papillomavirus-positive oropharyngeal cancer
The objective of the current study was to determine the optimal individualized surveillance strategies for human papillomavirus (HPV)-positive oropharyngeal cancer. A consecutive cohort of 1,146 HPV-positive oropharyngeal cancer patients treated by intensity-modulated radiation therapy between 2013 and 2023 was included. The primary endpoint was the power of detecting recurrence at each follow-up. Three distinct, stage-specific follow-up strategies were developed based on the monthly probability of disease recurrence. Over a 5-year post-treatment period, the total number of follow-up visits was 10, 11, and 12 for Stages I, II, and III, respectively. These risk-adapted follow-up strategies demonstrated superior detection efficiency when compared to existing clinical guidelines. Furthermore, validation using Markov decision-analytic models confirmed that the risk-based strategies were both more effective and cost-efficient than the guideline-recommended strategy. Compared to the surveillance strategies recommended by the clinical guidelines, our proposed approach for HPV-positive oropharyngeal cancer demonstrated greater cost-effectiveness.
Authors
- Sean Matthew McBride (ORCID: https://orcid.org/0000-0002-9676-1669)
- Nadeem Riaz (ORCID: https://orcid.org/0000-0001-9873-5862)
- Yao Yu (ORCID: https://orcid.org/0000-0002-2814-4482)
- Lara Ann Dunn (ORCID: https://orcid.org/0000-0001-5318-2571)
- Eric Jeffrey Sherman (ORCID: https://orcid.org/0000-0002-4960-4783)
- Achraf A. Shamseddine (ORCID: https://orcid.org/0000-0003-3686-5850)
- Caineng Cao (ORCID: https://orcid.org/0000-0002-2803-0864)
- Nancy Y. Lee
- Winston Wong
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Zhejiang Cancer Hospital (CN)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.xcrm.2025.102472
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute